nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—SLC25A6—exocrine gland—uterine cancer	0.0347	0.0912	CbGeAlD
Clodronate—SLC25A5—exocrine gland—uterine cancer	0.0302	0.0793	CbGeAlD
Clodronate—SLC25A5—myometrium—uterine cancer	0.0167	0.044	CbGeAlD
Clodronate—Acute leukaemia—Medroxyprogesterone Acetate—uterine cancer	0.0163	0.0382	CcSEcCtD
Clodronate—SLC25A6—epithelium—uterine cancer	0.0151	0.0397	CbGeAlD
Clodronate—SLC25A6—uterine cervix—uterine cancer	0.015	0.0393	CbGeAlD
Clodronate—SLC25A5—Interactions of Vpr with host cellular proteins—HMGA1—uterine cancer	0.0145	0.075	CbGpPWpGaD
Clodronate—Myeloid leukaemia—Epirubicin—uterine cancer	0.014	0.0329	CcSEcCtD
Clodronate—SLC25A6—renal system—uterine cancer	0.014	0.0368	CbGeAlD
Clodronate—SLC25A5—epithelium—uterine cancer	0.0131	0.0345	CbGeAlD
Clodronate—SLC25A5—uterine cervix—uterine cancer	0.013	0.0342	CbGeAlD
Clodronate—Myeloid leukaemia—Doxorubicin—uterine cancer	0.013	0.0304	CcSEcCtD
Clodronate—SLC25A5—smooth muscle tissue—uterine cancer	0.0126	0.0332	CbGeAlD
Clodronate—SLC25A6—uterus—uterine cancer	0.0125	0.0328	CbGeAlD
Clodronate—SLC25A5—decidua—uterine cancer	0.0124	0.0326	CbGeAlD
Clodronate—SLC25A5—renal system—uterine cancer	0.0122	0.032	CbGeAlD
Clodronate—SLC25A6—Interactions of Vpr with host cellular proteins—HMGA1—uterine cancer	0.0121	0.0628	CbGpPWpGaD
Clodronate—SLC25A5—endometrium—uterine cancer	0.0118	0.0309	CbGeAlD
Clodronate—SLC25A4—decidua—uterine cancer	0.0116	0.0305	CbGeAlD
Clodronate—SLC25A4—renal system—uterine cancer	0.0114	0.03	CbGeAlD
Clodronate—SLC25A5—mammalian vulva—uterine cancer	0.0114	0.0299	CbGeAlD
Clodronate—SLC25A6—female reproductive system—uterine cancer	0.0112	0.0295	CbGeAlD
Clodronate—Extravasation—Carboplatin—uterine cancer	0.0112	0.0263	CcSEcCtD
Clodronate—SLC25A5—uterus—uterine cancer	0.0108	0.0285	CbGeAlD
Clodronate—SLC25A6—female gonad—uterine cancer	0.0102	0.0268	CbGeAlD
Clodronate—SLC25A5—female reproductive system—uterine cancer	0.00975	0.0256	CbGeAlD
Clodronate—SLC25A4—Interactions of Vpr with host cellular proteins—HMGA1—uterine cancer	0.00947	0.049	CbGpPWpGaD
Clodronate—Acute leukaemia—Etoposide—uterine cancer	0.00919	0.0215	CcSEcCtD
Clodronate—SLC25A4—female reproductive system—uterine cancer	0.00913	0.024	CbGeAlD
Clodronate—Foetor hepaticus—Progesterone—uterine cancer	0.00905	0.0212	CcSEcCtD
Clodronate—Acute myeloid leukaemia—Epirubicin—uterine cancer	0.00897	0.021	CcSEcCtD
Clodronate—SLC25A5—female gonad—uterine cancer	0.00887	0.0233	CbGeAlD
Clodronate—SLC25A5—vagina—uterine cancer	0.00881	0.0232	CbGeAlD
Clodronate—SLC25A4—female gonad—uterine cancer	0.00831	0.0219	CbGeAlD
Clodronate—Acute myeloid leukaemia—Doxorubicin—uterine cancer	0.0083	0.0195	CcSEcCtD
Clodronate—SLC25A4—vagina—uterine cancer	0.00826	0.0217	CbGeAlD
Clodronate—Foetor hepaticus—Medroxyprogesterone Acetate—uterine cancer	0.0082	0.0192	CcSEcCtD
Clodronate—Digestion impaired—Progesterone—uterine cancer	0.00768	0.018	CcSEcCtD
Clodronate—Liver disorder—Progesterone—uterine cancer	0.00753	0.0177	CcSEcCtD
Clodronate—Digestion impaired—Medroxyprogesterone Acetate—uterine cancer	0.00696	0.0163	CcSEcCtD
Clodronate—Liver disorder—Medroxyprogesterone Acetate—uterine cancer	0.00682	0.016	CcSEcCtD
Clodronate—Hypercalcaemia—Medroxyprogesterone Acetate—uterine cancer	0.0067	0.0157	CcSEcCtD
Clodronate—SLC25A6—lymph node—uterine cancer	0.00655	0.0172	CbGeAlD
Clodronate—PTGS2—artery—uterine cancer	0.00651	0.0171	CbGeAlD
Clodronate—Neoplasm malignant—Progesterone—uterine cancer	0.00601	0.0141	CcSEcCtD
Clodronate—SLC25A5—lymph node—uterine cancer	0.0057	0.015	CbGeAlD
Clodronate—Hypocalcaemia—Progesterone—uterine cancer	0.00561	0.0131	CcSEcCtD
Clodronate—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.00545	0.0128	CcSEcCtD
Clodronate—SLC25A4—lymph node—uterine cancer	0.00534	0.014	CbGeAlD
Clodronate—Proteinuria—Medroxyprogesterone Acetate—uterine cancer	0.00529	0.0124	CcSEcCtD
Clodronate—Protein urine present—Medroxyprogesterone Acetate—uterine cancer	0.00522	0.0122	CcSEcCtD
Clodronate—Acute leukaemia—Epirubicin—uterine cancer	0.00515	0.0121	CcSEcCtD
Clodronate—Hepatocellular injury—Progesterone—uterine cancer	0.00513	0.012	CcSEcCtD
Clodronate—SLC25A5—Host Interactions of HIV factors—HMGA1—uterine cancer	0.00508	0.0263	CbGpPWpGaD
Clodronate—Acute leukaemia—Doxorubicin—uterine cancer	0.00477	0.0112	CcSEcCtD
Clodronate—SLC25A5—Integration of energy metabolism—STK11—uterine cancer	0.00473	0.0245	CbGpPWpGaD
Clodronate—Hepatocellular injury—Medroxyprogesterone Acetate—uterine cancer	0.00465	0.0109	CcSEcCtD
Clodronate—Hyperphosphataemia—Epirubicin—uterine cancer	0.00431	0.0101	CcSEcCtD
Clodronate—Hepatic function abnormal—Progesterone—uterine cancer	0.00426	0.01	CcSEcCtD
Clodronate—SLC25A6—Host Interactions of HIV factors—HMGA1—uterine cancer	0.00425	0.022	CbGpPWpGaD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.0042	0.0217	CbGpPWpGaD
Clodronate—Extravasation—Dactinomycin—uterine cancer	0.00416	0.00975	CcSEcCtD
Clodronate—Hyperphosphataemia—Doxorubicin—uterine cancer	0.00399	0.00935	CcSEcCtD
Clodronate—SLC25A6—Integration of energy metabolism—STK11—uterine cancer	0.00397	0.0205	CbGpPWpGaD
Clodronate—Hypocalcaemia—Dactinomycin—uterine cancer	0.00396	0.00929	CcSEcCtD
Clodronate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—uterine cancer	0.00391	0.0202	CbGpPWpGaD
Clodronate—Hepatic function abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00386	0.00906	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—TSPYL2—uterine cancer	0.00365	0.0189	CbGpPWpGaD
Clodronate—Infection—Carboplatin—uterine cancer	0.00346	0.00812	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—HMGA1—uterine cancer	0.00332	0.0172	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—HMGA1—uterine cancer	0.0033	0.0171	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Progesterone—uterine cancer	0.00329	0.0077	CcSEcCtD
Clodronate—Dysphagia—Progesterone—uterine cancer	0.00322	0.00755	CcSEcCtD
Clodronate—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.00316	0.00742	CcSEcCtD
Clodronate—PTGS2—myometrium—uterine cancer	0.00315	0.00828	CbGeAlD
Clodronate—SLC25A4—Integration of energy metabolism—STK11—uterine cancer	0.0031	0.016	CbGpPWpGaD
Clodronate—Extravasation—Etoposide—uterine cancer	0.00301	0.00706	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Medroxyprogesterone Acetate—uterine cancer	0.00298	0.00698	CcSEcCtD
Clodronate—Dysphagia—Medroxyprogesterone Acetate—uterine cancer	0.00292	0.00684	CcSEcCtD
Clodronate—Pneumonia—Progesterone—uterine cancer	0.00289	0.00677	CcSEcCtD
Clodronate—Bronchospasm—Medroxyprogesterone Acetate—uterine cancer	0.00287	0.00673	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—TSPYL2—uterine cancer	0.00285	0.0147	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—HMGA1—uterine cancer	0.00276	0.0143	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.00267	0.0138	CbGpPWpGaD
Clodronate—Local reaction—Epirubicin—uterine cancer	0.00266	0.00623	CcSEcCtD
Clodronate—Pharyngitis—Progesterone—uterine cancer	0.00256	0.006	CcSEcCtD
Clodronate—Urinary tract disorder—Progesterone—uterine cancer	0.00255	0.00597	CcSEcCtD
Clodronate—Connective tissue disorder—Progesterone—uterine cancer	0.00253	0.00594	CcSEcCtD
Clodronate—Urethral disorder—Progesterone—uterine cancer	0.00253	0.00592	CcSEcCtD
Clodronate—PTGS2—epithelium—uterine cancer	0.00247	0.0065	CbGeAlD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.00247	0.0128	CbGpPWpGaD
Clodronate—Local reaction—Doxorubicin—uterine cancer	0.00246	0.00577	CcSEcCtD
Clodronate—PTGS2—uterine cervix—uterine cancer	0.00245	0.00644	CbGeAlD
Clodronate—Serum creatinine increased—Epirubicin—uterine cancer	0.00239	0.00561	CcSEcCtD
Clodronate—PTGS2—smooth muscle tissue—uterine cancer	0.00238	0.00626	CbGeAlD
Clodronate—Mediastinal disorder—Progesterone—uterine cancer	0.00232	0.00545	CcSEcCtD
Clodronate—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00232	0.00544	CcSEcCtD
Clodronate—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00541	CcSEcCtD
Clodronate—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.0023	0.00538	CcSEcCtD
Clodronate—PTGS2—renal system—uterine cancer	0.00229	0.00603	CbGeAlD
Clodronate—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00229	0.00537	CcSEcCtD
Clodronate—Dysphagia—Dactinomycin—uterine cancer	0.00228	0.00534	CcSEcCtD
Clodronate—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00225	0.0116	CbGpPWpGaD
Clodronate—PTGS2—endometrium—uterine cancer	0.00222	0.00583	CbGeAlD
Clodronate—Serum creatinine increased—Doxorubicin—uterine cancer	0.00221	0.00519	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—HMGA1—uterine cancer	0.00216	0.0112	CbGpPWpGaD
Clodronate—Hypercalcaemia—Epirubicin—uterine cancer	0.00212	0.00497	CcSEcCtD
Clodronate—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00211	0.00494	CcSEcCtD
Clodronate—Anaemia—Progesterone—uterine cancer	0.00207	0.00486	CcSEcCtD
Clodronate—Angioedema—Progesterone—uterine cancer	0.00205	0.00481	CcSEcCtD
Clodronate—Pneumonia—Dactinomycin—uterine cancer	0.00204	0.00479	CcSEcCtD
Clodronate—PTGS2—uterus—uterine cancer	0.00204	0.00537	CbGeAlD
Clodronate—Hypercalcaemia—Doxorubicin—uterine cancer	0.00196	0.0046	CcSEcCtD
Clodronate—Cardiac failure—Etoposide—uterine cancer	0.00195	0.00458	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.0019	0.00445	CcSEcCtD
Clodronate—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00188	0.00441	CcSEcCtD
Clodronate—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00186	0.00436	CcSEcCtD
Clodronate—PTGS2—female reproductive system—uterine cancer	0.00184	0.00483	CbGeAlD
Clodronate—Infection—Progesterone—uterine cancer	0.00182	0.00427	CcSEcCtD
Clodronate—Pharyngitis—Dactinomycin—uterine cancer	0.00181	0.00424	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.0018	0.00934	CbGpPWpGaD
Clodronate—Skin disorder—Progesterone—uterine cancer	0.00178	0.00417	CcSEcCtD
Clodronate—Anorexia—Progesterone—uterine cancer	0.00175	0.00409	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—uterine cancer	0.00172	0.00404	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00172	0.00403	CcSEcCtD
Clodronate—SLC25A5—Metabolism—SRD5A2—uterine cancer	0.0017	0.0088	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NDUFB11—uterine cancer	0.0017	0.0088	CbGpPWpGaD
Clodronate—Extravasation—Epirubicin—uterine cancer	0.00169	0.00396	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Etoposide—uterine cancer	0.00168	0.00394	CcSEcCtD
Clodronate—PTGS2—female gonad—uterine cancer	0.00167	0.00439	CbGeAlD
Clodronate—PTGS2—vagina—uterine cancer	0.00166	0.00436	CbGeAlD
Clodronate—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.00387	CcSEcCtD
Clodronate—Dysphagia—Etoposide—uterine cancer	0.00165	0.00386	CcSEcCtD
Clodronate—Dyspnoea—Progesterone—uterine cancer	0.00163	0.00383	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—INHBA—uterine cancer	0.00163	0.00844	CbGpPWpGaD
Clodronate—Bronchospasm—Etoposide—uterine cancer	0.00162	0.0038	CcSEcCtD
Clodronate—Dyspepsia—Progesterone—uterine cancer	0.00161	0.00378	CcSEcCtD
Clodronate—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00378	CcSEcCtD
Clodronate—Hypocalcaemia—Epirubicin—uterine cancer	0.00161	0.00377	CcSEcCtD
Clodronate—Oliguria—Epirubicin—uterine cancer	0.0016	0.00374	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—uterine cancer	0.0016	0.00374	CcSEcCtD
Clodronate—Decreased appetite—Progesterone—uterine cancer	0.00159	0.00373	CcSEcCtD
Clodronate—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00371	CcSEcCtD
Clodronate—Gastrointestinal disorder—Progesterone—uterine cancer	0.00158	0.00371	CcSEcCtD
Clodronate—SLC25A5—Disease—AKR1B10—uterine cancer	0.00158	0.00818	CbGpPWpGaD
Clodronate—Extravasation—Doxorubicin—uterine cancer	0.00156	0.00366	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—uterine cancer	0.00155	0.00363	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—MME—uterine cancer	0.00153	0.00793	CbGpPWpGaD
Clodronate—Hypocalcaemia—Doxorubicin—uterine cancer	0.00149	0.00349	CcSEcCtD
Clodronate—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00148	0.00347	CcSEcCtD
Clodronate—Oliguria—Doxorubicin—uterine cancer	0.00148	0.00346	CcSEcCtD
Clodronate—Pneumonia—Etoposide—uterine cancer	0.00148	0.00346	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—uterine cancer	0.00147	0.00345	CcSEcCtD
Clodronate—Anaemia—Dactinomycin—uterine cancer	0.00147	0.00344	CcSEcCtD
Clodronate—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00342	CcSEcCtD
Clodronate—Urticaria—Progesterone—uterine cancer	0.00146	0.00341	CcSEcCtD
Clodronate—Abdominal pain—Progesterone—uterine cancer	0.00145	0.00339	CcSEcCtD
Clodronate—Renal failure—Etoposide—uterine cancer	0.00144	0.00339	CcSEcCtD
Clodronate—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00338	CcSEcCtD
Clodronate—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00336	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—uterine cancer	0.00143	0.00335	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SRD5A2—uterine cancer	0.00142	0.00738	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NDUFB11—uterine cancer	0.00142	0.00738	CbGpPWpGaD
Clodronate—PTGS2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00141	0.00731	CbGpPWpGaD
Clodronate—Hepatocellular injury—Doxorubicin—uterine cancer	0.00136	0.00319	CcSEcCtD
Clodronate—SLC25A6—Disease—AKR1B10—uterine cancer	0.00132	0.00685	CbGpPWpGaD
Clodronate—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00309	CcSEcCtD
Clodronate—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00308	CcSEcCtD
Clodronate—SLC25A5—Disease—RNF43—uterine cancer	0.00131	0.00677	CbGpPWpGaD
Clodronate—Urinary tract disorder—Etoposide—uterine cancer	0.0013	0.00305	CcSEcCtD
Clodronate—Pruritus—Progesterone—uterine cancer	0.0013	0.00304	CcSEcCtD
Clodronate—Urethral disorder—Etoposide—uterine cancer	0.00129	0.00303	CcSEcCtD
Clodronate—Infection—Dactinomycin—uterine cancer	0.00129	0.00301	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—INHBA—uterine cancer	0.00127	0.00659	CbGpPWpGaD
Clodronate—Diarrhoea—Progesterone—uterine cancer	0.00125	0.00294	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00125	0.00646	CbGpPWpGaD
Clodronate—Anorexia—Dactinomycin—uterine cancer	0.00123	0.00289	CcSEcCtD
Clodronate—SLC25A5—Metabolism—AKR1B1—uterine cancer	0.00123	0.00637	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—STAR—uterine cancer	0.00123	0.00637	CbGpPWpGaD
Clodronate—Hepatic function abnormal—Epirubicin—uterine cancer	0.00122	0.00287	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MME—uterine cancer	0.0012	0.00619	CbGpPWpGaD
Clodronate—Mediastinal disorder—Etoposide—uterine cancer	0.00119	0.00279	CcSEcCtD
Clodronate—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00275	CcSEcCtD
Clodronate—Vomiting—Progesterone—uterine cancer	0.00116	0.00273	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—uterine cancer	0.00116	0.00271	CcSEcCtD
Clodronate—Rash—Progesterone—uterine cancer	0.00115	0.00271	CcSEcCtD
Clodronate—Dermatitis—Progesterone—uterine cancer	0.00115	0.0027	CcSEcCtD
Clodronate—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00266	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—uterine cancer	0.00113	0.00265	CcSEcCtD
Clodronate—Decreased appetite—Dactinomycin—uterine cancer	0.00113	0.00264	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—uterine cancer	0.00112	0.00263	CcSEcCtD
Clodronate—SLC25A4—Metabolism—NDUFB11—uterine cancer	0.00111	0.00576	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SRD5A2—uterine cancer	0.00111	0.00576	CbGpPWpGaD
Clodronate—PTGS2—Overview of nanoparticle effects—CXCL8—uterine cancer	0.00111	0.00574	CbGpPWpGaD
Clodronate—SLC25A6—Disease—RNF43—uterine cancer	0.0011	0.00568	CbGpPWpGaD
Clodronate—Cardiac failure—Epirubicin—uterine cancer	0.00109	0.00257	CcSEcCtD
Clodronate—Nausea—Progesterone—uterine cancer	0.00109	0.00255	CcSEcCtD
Clodronate—SLC25A5—Disease—AKR1C1—uterine cancer	0.00108	0.00558	CbGpPWpGaD
Clodronate—PTGS2—lymph node—uterine cancer	0.00107	0.00282	CbGeAlD
Clodronate—Renal failure acute—Doxorubicin—uterine cancer	0.00107	0.00251	CcSEcCtD
Clodronate—Anaemia—Etoposide—uterine cancer	0.00106	0.00249	CcSEcCtD
Clodronate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00247	CcSEcCtD
Clodronate—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00245	CcSEcCtD
Clodronate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00245	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.00104	0.00539	CbGpPWpGaD
Clodronate—Renal impairment—Doxorubicin—uterine cancer	0.00104	0.00244	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.00103	0.00535	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKR1B10—uterine cancer	0.00103	0.00535	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKR1B1—uterine cancer	0.00103	0.00533	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—STAR—uterine cancer	0.00103	0.00533	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—GPX3—uterine cancer	0.00102	0.0053	CbGpPWpGaD
Clodronate—Abdominal pain—Dactinomycin—uterine cancer	0.00102	0.0024	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—uterine cancer	0.00101	0.00238	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—FBXW7—uterine cancer	0.00101	0.00521	CbGpPWpGaD
Clodronate—Blood creatinine increased—Epirubicin—uterine cancer	0.001	0.00235	CcSEcCtD
Clodronate—Dehydration—Epirubicin—uterine cancer	0.000994	0.00233	CcSEcCtD
Clodronate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000986	0.00231	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	0.000977	0.00506	CbGpPWpGaD
Clodronate—Abdominal pain upper—Epirubicin—uterine cancer	0.000976	0.00229	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000971	0.00228	CcSEcCtD
Clodronate—SLC25A5—Metabolism—POLD1—uterine cancer	0.000965	0.00499	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.00096	0.00497	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000942	0.00221	CcSEcCtD
Clodronate—SLC25A5—Disease—DCN—uterine cancer	0.000932	0.00483	CbGpPWpGaD
Clodronate—Infection—Etoposide—uterine cancer	0.000931	0.00218	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—uterine cancer	0.000926	0.00217	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—uterine cancer	0.000924	0.00217	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—uterine cancer	0.00092	0.00216	CcSEcCtD
Clodronate—Skin disorder—Etoposide—uterine cancer	0.00091	0.00213	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—uterine cancer	0.000903	0.00212	CcSEcCtD
Clodronate—SLC25A6—Disease—AKR1C1—uterine cancer	0.000903	0.00468	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKR1C1—uterine cancer	0.000902	0.00467	CbGpPWpGaD
Clodronate—PTGS2—S1P1 pathway—VEGFA—uterine cancer	0.0009	0.00466	CbGpPWpGaD
Clodronate—Anorexia—Etoposide—uterine cancer	0.000893	0.00209	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000892	0.00462	CbGpPWpGaD
Clodronate—Diarrhoea—Dactinomycin—uterine cancer	0.000886	0.00208	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000872	0.00204	CcSEcCtD
Clodronate—SLC25A4—Disease—RNF43—uterine cancer	0.000856	0.00443	CbGpPWpGaD
Clodronate—Dysphagia—Doxorubicin—uterine cancer	0.000855	0.002	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000845	0.00438	CbGpPWpGaD
Clodronate—Dyspnoea—Etoposide—uterine cancer	0.000835	0.00196	CcSEcCtD
Clodronate—SLC25A5—Disease—AKR1C3—uterine cancer	0.000829	0.00429	CbGpPWpGaD
Clodronate—Pneumonia—Epirubicin—uterine cancer	0.000828	0.00194	CcSEcCtD
Clodronate—Vomiting—Dactinomycin—uterine cancer	0.000823	0.00193	CcSEcCtD
Clodronate—Rash—Dactinomycin—uterine cancer	0.000816	0.00191	CcSEcCtD
Clodronate—Decreased appetite—Etoposide—uterine cancer	0.000814	0.00191	CcSEcCtD
Clodronate—Renal failure—Epirubicin—uterine cancer	0.000809	0.0019	CcSEcCtD
Clodronate—Gastrointestinal disorder—Etoposide—uterine cancer	0.000809	0.0019	CcSEcCtD
Clodronate—SLC25A6—Metabolism—POLD1—uterine cancer	0.000808	0.00419	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HMGA1—uterine cancer	0.000808	0.00419	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—STAR—uterine cancer	0.000804	0.00416	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—RRM2—uterine cancer	0.000804	0.00416	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKR1B1—uterine cancer	0.000804	0.00416	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—FBXW7—uterine cancer	0.000786	0.00407	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000785	0.00407	CbGpPWpGaD
Clodronate—SLC25A6—Disease—DCN—uterine cancer	0.000781	0.00405	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—DCN—uterine cancer	0.000781	0.00404	CbGpPWpGaD
Clodronate—Nausea—Dactinomycin—uterine cancer	0.000769	0.0018	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—uterine cancer	0.000766	0.0018	CcSEcCtD
Clodronate—SLC25A6—Metabolism—AKR1C1—uterine cancer	0.000756	0.00392	CbGpPWpGaD
Clodronate—Renal failure—Doxorubicin—uterine cancer	0.000749	0.00176	CcSEcCtD
Clodronate—Urticaria—Etoposide—uterine cancer	0.000744	0.00174	CcSEcCtD
Clodronate—Abdominal pain—Etoposide—uterine cancer	0.000741	0.00174	CcSEcCtD
Clodronate—SLC25A5—Disease—FBXW7—uterine cancer	0.000739	0.00383	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CYP11A1—uterine cancer	0.000736	0.00381	CbGpPWpGaD
Clodronate—Pharyngitis—Epirubicin—uterine cancer	0.000734	0.00172	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—uterine cancer	0.00073	0.00171	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—uterine cancer	0.000726	0.0017	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—uterine cancer	0.000725	0.0017	CcSEcCtD
Clodronate—SLC25A4—Disease—AKR1C1—uterine cancer	0.000705	0.00365	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000697	0.00361	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKR1C3—uterine cancer	0.000695	0.0036	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKR1C3—uterine cancer	0.000695	0.0036	CbGpPWpGaD
Clodronate—Pharyngitis—Doxorubicin—uterine cancer	0.000679	0.00159	CcSEcCtD
Clodronate—SLC25A6—Disease—HMGA1—uterine cancer	0.000677	0.00351	CbGpPWpGaD
Clodronate—Urinary tract disorder—Doxorubicin—uterine cancer	0.000676	0.00158	CcSEcCtD
Clodronate—SLC25A6—Metabolism—RRM2—uterine cancer	0.000674	0.00349	CbGpPWpGaD
Clodronate—Connective tissue disorder—Doxorubicin—uterine cancer	0.000672	0.00158	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—uterine cancer	0.000671	0.00157	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—uterine cancer	0.000666	0.00156	CcSEcCtD
Clodronate—Pruritus—Etoposide—uterine cancer	0.000663	0.00155	CcSEcCtD
Clodronate—SLC25A6—Metabolism—DCN—uterine cancer	0.000654	0.00339	CbGpPWpGaD
Clodronate—Diarrhoea—Etoposide—uterine cancer	0.000641	0.0015	CcSEcCtD
Clodronate—SLC25A4—Metabolism—POLD1—uterine cancer	0.000631	0.00327	CbGpPWpGaD
Clodronate—SLC25A6—Disease—FBXW7—uterine cancer	0.00062	0.00321	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—uterine cancer	0.000616	0.00145	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CYP11A1—uterine cancer	0.000616	0.00319	CbGpPWpGaD
Clodronate—SLC25A4—Disease—DCN—uterine cancer	0.00061	0.00316	CbGpPWpGaD
Clodronate—Vomiting—Etoposide—uterine cancer	0.000596	0.0014	CcSEcCtD
Clodronate—Anaemia—Epirubicin—uterine cancer	0.000595	0.00139	CcSEcCtD
Clodronate—Rash—Etoposide—uterine cancer	0.000591	0.00138	CcSEcCtD
Clodronate—SLC25A4—Metabolism—AKR1C1—uterine cancer	0.00059	0.00306	CbGpPWpGaD
Clodronate—Dermatitis—Etoposide—uterine cancer	0.00059	0.00138	CcSEcCtD
Clodronate—SLC25A6—Metabolism—AKR1C3—uterine cancer	0.000582	0.00301	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN2B—uterine cancer	0.000579	0.003	CbGpPWpGaD
Clodronate—Nausea—Etoposide—uterine cancer	0.000557	0.0013	CcSEcCtD
Clodronate—Anaemia—Doxorubicin—uterine cancer	0.00055	0.00129	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000544	0.00128	CcSEcCtD
Clodronate—SLC25A4—Disease—AKR1C3—uterine cancer	0.000543	0.00281	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—STK11—uterine cancer	0.000541	0.0028	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CYP19A1—uterine cancer	0.000541	0.0028	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000534	0.00276	CbGpPWpGaD
Clodronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.000531	0.00275	CbGpPWpGaD
Clodronate—SLC25A5—Disease—SMAD3—uterine cancer	0.000529	0.00274	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HMGA1—uterine cancer	0.000529	0.00274	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—RRM2—uterine cancer	0.000526	0.00272	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000526	0.00272	CbGpPWpGaD
Clodronate—Infection—Epirubicin—uterine cancer	0.000522	0.00122	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CCL2—uterine cancer	0.000517	0.00268	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	0.000511	0.00265	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—DCN—uterine cancer	0.000511	0.00264	CbGpPWpGaD
Clodronate—Skin disorder—Epirubicin—uterine cancer	0.00051	0.0012	CcSEcCtD
Clodronate—SLC25A5—Disease—FGFR2—uterine cancer	0.000504	0.00261	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000503	0.00118	CcSEcCtD
Clodronate—Anorexia—Epirubicin—uterine cancer	0.000501	0.00117	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000494	0.00256	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MTHFR—uterine cancer	0.000486	0.00251	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN2B—uterine cancer	0.000485	0.00251	CbGpPWpGaD
Clodronate—SLC25A4—Disease—FBXW7—uterine cancer	0.000484	0.0025	CbGpPWpGaD
Clodronate—Infection—Doxorubicin—uterine cancer	0.000483	0.00113	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CYP11A1—uterine cancer	0.000481	0.00249	CbGpPWpGaD
Clodronate—Skin disorder—Doxorubicin—uterine cancer	0.000472	0.00111	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000469	0.00243	CbGpPWpGaD
Clodronate—Dyspnoea—Epirubicin—uterine cancer	0.000468	0.0011	CcSEcCtD
Clodronate—Anorexia—Doxorubicin—uterine cancer	0.000463	0.00109	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—uterine cancer	0.000462	0.00108	CcSEcCtD
Clodronate—Decreased appetite—Epirubicin—uterine cancer	0.000457	0.00107	CcSEcCtD
Clodronate—SLC25A4—Metabolism—AKR1C3—uterine cancer	0.000454	0.00235	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—STK11—uterine cancer	0.000453	0.00235	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CYP19A1—uterine cancer	0.000453	0.00235	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000453	0.00106	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000447	0.00232	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000444	0.0023	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SMAD3—uterine cancer	0.000443	0.00229	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000438	0.00227	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—uterine cancer	0.000433	0.00102	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—uterine cancer	0.000428	0.001	CcSEcCtD
Clodronate—SLC25A6—Disease—FGFR2—uterine cancer	0.000423	0.00219	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—uterine cancer	0.000422	0.00099	CcSEcCtD
Clodronate—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.00042	0.000984	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000417	0.00216	CbGpPWpGaD
Clodronate—Urticaria—Epirubicin—uterine cancer	0.000417	0.000978	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—uterine cancer	0.000415	0.000973	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000414	0.00215	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000411	0.00213	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CXCL8—uterine cancer	0.000409	0.00212	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MTHFR—uterine cancer	0.000407	0.00211	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—MTHFR—uterine cancer	0.000407	0.00211	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CCL2—uterine cancer	0.000404	0.00209	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—uterine cancer	0.000386	0.000905	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—uterine cancer	0.000384	0.000901	CcSEcCtD
Clodronate—SLC25A4—Disease—CDKN2B—uterine cancer	0.000379	0.00196	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CTNNB1—uterine cancer	0.000377	0.00195	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000377	0.00195	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000376	0.00195	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000372	0.00193	CbGpPWpGaD
Clodronate—Pruritus—Epirubicin—uterine cancer	0.000372	0.000871	CcSEcCtD
Clodronate—Diarrhoea—Epirubicin—uterine cancer	0.000359	0.000842	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000357	0.00185	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000357	0.00185	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—STK11—uterine cancer	0.000354	0.00183	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP19A1—uterine cancer	0.000354	0.00183	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SMAD3—uterine cancer	0.000346	0.00179	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—uterine cancer	0.000344	0.000806	CcSEcCtD
Clodronate—SLC25A6—Metabolism—MTHFR—uterine cancer	0.000341	0.00176	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000337	0.00175	CbGpPWpGaD
Clodronate—Vomiting—Epirubicin—uterine cancer	0.000334	0.000783	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—uterine cancer	0.000332	0.000779	CcSEcCtD
Clodronate—Rash—Epirubicin—uterine cancer	0.000331	0.000776	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—uterine cancer	0.000331	0.000776	CcSEcCtD
Clodronate—SLC25A4—Disease—FGFR2—uterine cancer	0.00033	0.00171	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.00033	0.00171	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	0.000325	0.00168	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000321	0.00166	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CXCL8—uterine cancer	0.000319	0.00165	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MTHFR—uterine cancer	0.000318	0.00164	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ERBB2—uterine cancer	0.000317	0.00164	CbGpPWpGaD
Clodronate—Nausea—Epirubicin—uterine cancer	0.000312	0.000731	CcSEcCtD
Clodronate—Vomiting—Doxorubicin—uterine cancer	0.000309	0.000724	CcSEcCtD
Clodronate—Rash—Doxorubicin—uterine cancer	0.000306	0.000718	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—uterine cancer	0.000306	0.000718	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—CTNNB1—uterine cancer	0.000295	0.00153	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN1B—uterine cancer	0.000293	0.00152	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	0.000289	0.0015	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—uterine cancer	0.000289	0.000677	CcSEcCtD
Clodronate—SLC25A5—Disease—CTNNB1—uterine cancer	0.000277	0.00144	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	0.000271	0.0014	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—uterine cancer	0.00027	0.0014	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—MTHFR—uterine cancer	0.000266	0.00138	CbGpPWpGaD
Clodronate—SLC25A6—Disease—ERBB2—uterine cancer	0.000265	0.00137	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000262	0.00136	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EP300—uterine cancer	0.000258	0.00133	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	0.000257	0.00133	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000251	0.0013	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	0.000251	0.0013	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1B—uterine cancer	0.000246	0.00127	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—uterine cancer	0.000241	0.00125	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	0.000233	0.00121	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—uterine cancer	0.000232	0.0012	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—uterine cancer	0.000226	0.00117	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—uterine cancer	0.000226	0.00117	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NDUFB11—uterine cancer	0.00022	0.00114	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SRD5A2—uterine cancer	0.00022	0.00114	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EP300—uterine cancer	0.000216	0.00112	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—EP300—uterine cancer	0.000216	0.00112	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000214	0.00111	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—uterine cancer	0.000207	0.00107	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—uterine cancer	0.000207	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKR1B10—uterine cancer	0.000204	0.00106	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—uterine cancer	0.000202	0.00105	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000202	0.00104	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	0.000198	0.00103	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1B—uterine cancer	0.000192	0.000994	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—uterine cancer	0.000191	0.000987	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—uterine cancer	0.00019	0.000982	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000185	0.000955	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—uterine cancer	0.000181	0.000939	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—EP300—uterine cancer	0.000181	0.000936	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—uterine cancer	0.000177	0.000915	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—uterine cancer	0.000176	0.000913	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—uterine cancer	0.000174	0.0009	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000171	0.000885	CbGpPWpGaD
Clodronate—PTGS2—Disease—RNF43—uterine cancer	0.000169	0.000876	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EP300—uterine cancer	0.000169	0.000873	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000161	0.000836	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—uterine cancer	0.00016	0.000827	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—uterine cancer	0.00016	0.000826	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKR1B1—uterine cancer	0.000159	0.000823	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—STAR—uterine cancer	0.000159	0.000823	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—uterine cancer	0.000158	0.000817	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—uterine cancer	0.000158	0.000816	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000157	0.000815	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000157	0.000814	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—uterine cancer	0.000156	0.000806	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.00015	0.000777	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—uterine cancer	0.000148	0.000766	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—uterine cancer	0.000148	0.000765	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000142	0.000736	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—EP300—uterine cancer	0.000141	0.000731	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKR1C1—uterine cancer	0.000139	0.000722	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—uterine cancer	0.000136	0.000703	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—uterine cancer	0.000134	0.000693	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—uterine cancer	0.00013	0.000676	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—uterine cancer	0.00013	0.000675	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—POLD1—uterine cancer	0.000125	0.000646	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—uterine cancer	0.000125	0.000646	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000121	0.000626	CbGpPWpGaD
Clodronate—PTGS2—Disease—DCN—uterine cancer	0.000121	0.000624	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKR1C1—uterine cancer	0.000117	0.000604	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—uterine cancer	0.000115	0.000597	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000111	0.000575	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—uterine cancer	0.000109	0.000566	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000107	0.000556	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKR1C3—uterine cancer	0.000107	0.000555	CbGpPWpGaD
Clodronate—PTGS2—Disease—HMGA1—uterine cancer	0.000105	0.000541	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—uterine cancer	0.000104	0.000541	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—RRM2—uterine cancer	0.000104	0.000539	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—uterine cancer	0.000102	0.000527	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—DCN—uterine cancer	0.000101	0.000523	CbGpPWpGaD
Clodronate—PTGS2—Disease—FBXW7—uterine cancer	9.56e-05	0.000495	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP11A1—uterine cancer	9.51e-05	0.000493	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.07e-05	0.00047	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKR1C3—uterine cancer	8.98e-05	0.000465	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—uterine cancer	8.53e-05	0.000442	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN2B—uterine cancer	7.49e-05	0.000388	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP19A1—uterine cancer	7e-05	0.000362	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—STK11—uterine cancer	7e-05	0.000362	CbGpPWpGaD
Clodronate—PTGS2—Disease—SMAD3—uterine cancer	6.84e-05	0.000354	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.57e-05	0.00034	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGFR2—uterine cancer	6.52e-05	0.000338	CbGpPWpGaD
Clodronate—PTGS2—Disease—MTHFR—uterine cancer	6.28e-05	0.000325	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.27e-05	0.000324	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MTHFR—uterine cancer	5.26e-05	0.000272	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.64e-05	0.00024	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—uterine cancer	4.1e-05	0.000212	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1B—uterine cancer	3.79e-05	0.000196	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—uterine cancer	3.58e-05	0.000186	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—uterine cancer	3.49e-05	0.000181	CbGpPWpGaD
Clodronate—PTGS2—Disease—EP300—uterine cancer	3.33e-05	0.000173	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—uterine cancer	3.12e-05	0.000161	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—uterine cancer	2.93e-05	0.000152	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—EP300—uterine cancer	2.79e-05	0.000144	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—uterine cancer	2.68e-05	0.000139	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—uterine cancer	2.46e-05	0.000128	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—uterine cancer	2.28e-05	0.000118	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—uterine cancer	2.06e-05	0.000107	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—uterine cancer	2.01e-05	0.000104	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—uterine cancer	1.69e-05	8.73e-05	CbGpPWpGaD
